TPG Weighs $5 Billion Sale of Claims-Data Platform Lyric

TPG is exploring a sale of Lyric, the healthcare software company behind one of the most widely used medical-claims editing systems in the United States, in a process that could value the business at about $5 billion. The possible transaction, first reported by Reuters on September 9, would test how buyers value an established, data-rich healthcare platform at a moment when artificial intelligence is both improving its products and threatening to lower the cost of competing with them.

The process remains preliminary. People familiar with the discussions said TPG is working with JPMorgan Chase, but they cautioned that there is no guarantee a deal will be completed. TPG and JPMorgan declined to comment to Reuters, and Lyric did not immediately respond. The reported valuation is based on approximately $250 million in annual earnings before interest, taxes, depreciation and amortization and a potential multiple of about 20 times that figure.

Lyric occupies a consequential point in the U.S. health-data chain: the moment between submission of a claim and movement of payment. Its software evaluates coding, clinical policy and documentation signals so health plans can identify inaccurate payments before money leaves the plan. Lyric says nine of the 10 largest U.S. health plans use its technology, which processes two million transactions an hour and 10 billion claim lines annually. Those are company figures, not independently audited disclosures, but they illustrate why a potential sale would matter well beyond private-equity markets.

A business built at the payment gate

Lyric traces its core claims-editing business to ClaimsXten, which TPG acquired for $2.2 billion in 2022. ClaimsXten had been part of Change Healthcare and was separated as UnitedHealth Group pursued its $13 billion acquisition of Change. In the litigation over that merger, a federal court described ClaimsXten as a first-pass claims-editing product and ultimately required the divestiture to TPG.

The court record shows why the asset was strategically sensitive. Without the divestiture, Change and UnitedHealth’s OptumInsight unit would have controlled more than 90% of the market for first-pass claims-editing solutions, according to evidence summarized in the opinion. The judge concluded that transferring ClaimsXten to TPG would preserve competition and ordered the sale. TPG renamed the company Lyric in 2023 and has since positioned it as a broader “healthcare decision intelligence” platform.

That evolution matters because claims editing is no longer simply a library of fixed billing rules. Modern platforms must reconcile payer policies, clinical documentation, procedure and diagnosis codes, contract terms, effective dates and exceptions at high speed. Lyric says its system supplies the rationale and source behind a recommendation, permits clients to configure rules and thresholds, and keeps clinical experts in the review process. The company also markets post-payment review, audit, provider-engagement and policy-management tools built around a common data foundation.

The scale behind payment accuracy

The addressable problem is large, but it is often described imprecisely. The Centers for Medicare & Medicaid Services estimated that Medicare fee-for-service made $28.83 billion in improper payments in fiscal 2025, equal to 6.55% of reviewed spending. Medicare Advantage’s estimate was $23.67 billion, while Medicaid’s was $37.39 billion. CMS emphasizes in its fact sheet that an improper payment is not automatically fraud: it can be an overpayment, an underpayment or a payment that reviewers cannot validate because required documentation is missing.

That distinction is essential. A platform designed to improve payment accuracy can address coding conflicts, incomplete records and policy mismatches without making a determination that anyone acted deceptively. CMS reported that 77.17% of Medicaid improper payments in its 2025 estimate resulted from insufficient documentation, generally not fraud or abuse. Most Medicare Advantage improper payments likewise reflected diagnosis data that supporting records did not substantiate.

Claims editors operate within a dense public rule set. CMS’s NCCI program, for example, publishes procedure-to-procedure and medically unlikely edits intended to promote correct coding and prevent inappropriate Medicare payments. Commercial insurers apply their own medical, reimbursement and contractual policies as well. Turning those requirements into consistent machine-readable logic—and updating that logic when rules change—is a data-governance task as much as a billing function.

The administrative burden extends beyond incorrect claims. The 2025 industry index from DataSpring, formerly CAQH, tracks the cost and adoption of electronic transactions across health plans and providers. Its current materials describe more than $20 billion in additional potential savings from greater automation. The measure is broader than claims editing, but it highlights the financial value attached to systems that reduce manual review, repeated submissions and avoidable reconciliation.

AI is both asset and competitive threat

TPG has said Lyric’s revenue growth accelerated after the acquisition and that artificial intelligence strengthens a business built on extensive claims data. AI can help classify documentation, compare a claim with multiple policy sources, prioritize complex cases and identify recurring patterns that can be converted into preventive edits. At sufficient scale, each resolved case can potentially improve the next recommendation, provided the feedback is governed and the underlying policy remains current.

But the same technology complicates a sale. Prospective buyers are evaluating whether newer AI-native companies could perform parts of the payment-integrity workflow more cheaply, Reuters reported. That creates two competing valuation stories. In one, Lyric’s historical data, embedded customer relationships, clinical expertise and established rule base form a durable advantage. In the other, generative and agentic systems make software development less expensive and erode the premium once assigned to incumbent platforms.

Healthcare raises the stakes because a superficially efficient decision can still be wrong. A rejected or delayed claim can shift work to clinicians, interrupt provider cash flow and expose patients to confusing bills. A paid claim that should have been flagged can increase premiums or public spending. The Office of Inspector General has previously found that some Medicare Advantage denials involved care that met Medicare coverage rules, illustrating the importance of separating payment accuracy from aggressive cost control. Its findings remain a warning that automation must be measured against clinical access, not only savings.

Evidence and governance will decide value

For health plans, the most valuable claims technology is not necessarily the model that produces the most flags. It is the system that produces defensible decisions with low error rates, clear policy provenance and a workable route for human review. Buyers examining Lyric will therefore need to test the quality of its recommendations, the age and representativeness of training and rules data, the frequency of overrides, appeal outcomes, provider friction and the speed with which policy changes reach production.

Security and data rights are equally material. Claims can contain protected health information and reveal commercially sensitive patterns about providers and insurers. The Change Healthcare litigation itself focused partly on whether control of a major electronic-data interchange could expose rivals’ competitively sensitive information. Any new owner would inherit obligations to maintain access controls, audit trails, contractual separation and resilience across a platform operating near the financial center of healthcare.

Public-sector experience also shows that analytics do not eliminate the need for governance. The Government Accountability Office reported that CMS’s antifraud analytics helped prevent an estimated $11.9 billion in potentially fraudulent Medicare payments from fiscal 2022 through 2024, while also identifying limitations in how effectiveness was measured. The GAO review reinforces a central lesson for private platforms: detection numbers are meaningful only when organizations can explain methodology, validate outcomes and distinguish prevented loss from alerts that would never have become improper payments.

What a sale would signal

A completed sale near $5 billion would more than double the $2.2 billion price TPG paid for ClaimsXten four years ago, although the comparison is imperfect because Lyric has expanded its product set and reportedly grown. It would indicate that buyers still assign substantial value to specialized healthcare datasets, workflow integration and domain-specific governance despite broader concern about AI’s effect on software valuations.

A lower price, a delayed process or no transaction would send a different signal: that the market is discounting traditional software advantages faster than incumbents can convert them into AI-era defensibility. That question is particularly acute in payment integrity, where the rules are complex and the data are valuable but the objective—finding inconsistencies among codes, policies and records—is increasingly suited to advanced automation.

For providers and patients, ownership is less important than how the platform behaves. The useful measures are whether accurate claims pass without needless delay, questionable claims receive explainable review, denials can be corrected promptly and policy changes are applied consistently. The reported Lyric process is therefore a financial event with an operational test embedded inside it: whether the next owner can turn scale and AI into more reliable decisions without adding opacity to an already difficult payment system.